Literature DB >> 29027217

Danger signals: Chemotherapy enhancers?

Thaiz Rivera Vargas1,2, Lionel Apetoh1,2,3.   

Abstract

Endogenous danger signals are molecules normally present in a given cell compartment that are rapidly released following cell stress and induce immune responses. We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, which rely on their release of danger signals such as the nuclear protein HMGB1. DNA can also be released from chemotherapy-treated tumor cells, act as a danger signal, and boost anticancer immunity. While the immunostimulatory properties of DNA have been identified for decades, the recent discovery of a novel family of receptors, cytosolic DNA sensors, has provided a novel impetus not only to understand how chemotherapy can trigger anticancer immune responses but also to exploit DNA-derived molecules for therapeutic use. We will here discuss the molecular characteristics of endogenous danger signals released from chemotherapy-treated tumor cells and focus on the clinical relevance of using these danger signals in chemoimmunotherapeutic strategies against cancer.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD8+ T cells; STING; adaptive immunity; cancer; chemotherapy; innate immunity

Mesh:

Substances:

Year:  2017        PMID: 29027217     DOI: 10.1111/imr.12581

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  19 in total

Review 1.  Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all.

Authors:  Muhammad Abdullah; Jessica M Berthiaume; Monte S Willis
Journal:  Transl Res       Date:  2017-11-07       Impact factor: 7.012

Review 2.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

Review 3.  PGC-1α participates in tumor chemoresistance by regulating glucose metabolism and mitochondrial function.

Authors:  Yanqing Li; Hu Hei; Songtao Zhang; Wenbo Gong; Yann Liu; Jianwu Qin
Journal:  Mol Cell Biochem       Date:  2022-06-17       Impact factor: 3.396

Review 4.  Immunotherapy and Biomarkers in Sarcoma.

Authors:  Thanate Dajsakdipon; Teerada Siripoon; Nuttapong Ngamphaiboon; Touch Ativitavas; Thitiya Dejthevaporn
Journal:  Curr Treat Options Oncol       Date:  2022-03-09

Review 5.  Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution.

Authors:  Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 6.  Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

Authors:  Thaiz Rivera Vargas; Lionel Apetoh
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 7.  Decoding inflammation, its causes, genomic responses, and emerging countermeasures.

Authors:  Jacek Hawiger; Jozef Zienkiewicz
Journal:  Scand J Immunol       Date:  2019-08-28       Impact factor: 3.487

8.  Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice.

Authors:  Guohao Wang; Junji Xu; Jiangsha Zhao; Weiqin Yin; Dayong Liu; WanJun Chen; Steven X Hou
Journal:  Nat Commun       Date:  2020-01-10       Impact factor: 14.919

9.  Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model.

Authors:  Sanambar Sadighi; Ramezanali Sharifian; Monireh Kazemimanesh; Ahad Muhammadnejad; Zahra Shahosseini; Saeid Amanpour; Samad Muhammadnejad
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

10.  Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death.

Authors:  Hongzhang Deng; Weijing Yang; Zijian Zhou; Rui Tian; Lisen Lin; Ying Ma; Jibin Song; Xiaoyuan Chen
Journal:  Nat Commun       Date:  2020-10-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.